Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2001

View Archived Issues

Company Profile: GW Pharmaceuticals

Phase II SBIR grant awarded to Immunicon for circulating cancer cell technology

Neotrofin increases hippocampal stem cells in mice

Helix BioPharma expands technology licensing agreement

Antigenics forms collaboration to test heat shock protein-based approach to HIV

Genomics-based company expands discovery program to include metabolic diseases

Results of phase II evaluation of NIL-A in Parkinson's disease reported

Dutch approval of Remeron SolTab

Genotropin approved in U.S. for growth failure in children born SGA

Hemosol to receive funding for discovery-stage hemoglobin-based oxygen carrier

Pipeline update included in Amgen's second quarter report

ICPD news: JP-1730 as a novel therapeutic approach to dyskinesias

Isis Pharmaceuticals provides Q2 2001 update

FDA advisory committee recommends approval of Forteo

Significant milestones achieved by Gilead in antiviral and other programs

Phase II trial of E21R for acute myeloid leukemia to start

FDA advisory committee reports results of FluMist evaluation

Major product development and corporate progress reported during first half of 2001 by NicOx

Milestone achieved in MorphoSys/GPC Biotech immunology antibody program

Japanese launch for combination antibiotic

New intraocular pressure-lowering agent introduced to Japanese market

Advanced Medicine claims new beta2-adrenoceptor agonists and their use

Opioid receptor ligands designed by Euroceltique particularly useful as analgesics

Akzo Nobel identifies new series of androgenic steroids

Series of adenosine antagonists reported by OSI in recent patent